key: cord-0751026-c2h0k11q
authors: Tau, Noam; Manuel, Oriol; Rozen-Zvi, Benaya; Shargian, Liat; Yahav, Dafna
title: Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2 – does one size fit all?
date: 2021-08-12
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.08.006
sha: 4efdd5e8600c2beeaea674e910234bd816727ef1
doc_id: 751026
cord_uid: c2h0k11q

nan

Phase III approval trials for the currently used vaccines for COVID-19 excluded 23 immunocompromised patients. Therefore, vaccine efficacy data in this population is only 24 available from real-life non-interventional studies, most assessing anti-SARS-CoV-2 antibodies 25 after vaccination. Although immunocompromised patients were excluded from all phase III vaccine approval trials 57 and there is still lack of data as to the real-world clinical efficacy of the currently used vaccines, 58 the data presented here is a source of concern. As countries are starting to ease social 59 distancing restrictions, and as international travel is resuming, there is an urgent need to identify 60 the specific populations at risk of being under-protected after receiving SARS-CoV-2 vaccines. In conclusion, emerging data from the global vaccine effort has shown diminished antibody 83 response in certain immunosuppressed populations, depending on underlying disease and type 84 of immunosuppression. We suggest that the most vulnerable populations would be identified in 85 ongoing, large-scale vaccine follow-up programs, and that people who belong to those 86 populations continue to practice special precautions as long as the COVID-19 pandemic is 87 ongoing. Further research is needed to assess the immunogenicity of other non-mRNA-based 88 vaccines among immunocompromised patients, characterize cellular immune response to 89 vaccination and define the correlation between immune response and actual risk of infection, 90

including severe outcomes. We also suggest continuing research already being conducted 91 using alternative vaccine regimens in a controlled manner in those populations, in order to 92 improve protection against SARS-CoV-2. 93

Antibody 104 Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant

Antibody 107 response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients -Prospective 108 cohort study

Low 110 immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Immunogenicity of the BNT162b2 mRNA Vaccine in Heart Transplanted Patients-A

Prospective Cohort Study

Transplant Recipients Treated with Belatacept

Serological response 124 to mRNA COVID-19 vaccines in IBD patients receiving biological therapies

Humoral 127 immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated 128 with high-efficacy disease-modifying therapies

Suboptimal response to COVID-19 mRNA 131 vaccines in hematologic malignancies patients

BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Covid-19 mRNA 137 Vaccination: Age and Immune Status and its Association with Axillary Lymph Node

Three Doses of an 144 mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients